We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-5.63%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.54B
AUM Growth
-$303M
Cap. Flow
-$71.8M
Cap. Flow %
-2.82%
Top 10 Hldgs %
38.38%
Holding
180
New
5
Increased
27
Reduced
36
Closed
3

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14M
2
ISRG icon
Intuitive Surgical
ISRG
+$11.4M
3
BSX icon
Boston Scientific
BSX
+$9.19M
4
AZN icon
AstraZeneca
AZN
+$8.8M
5
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$8.52M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$19.5M
2
MCK icon
McKesson
MCK
+$14.5M
3
MDT icon
Medtronic
MDT
+$11M
4
LLY icon
Eli Lilly
LLY
+$10.6M
5
ILMN icon
Illumina
ILMN
+$7.92M

Sector Composition

Rank Sector Weight
1 Healthcare 95.42%
2 Real Estate 3.13%
3 Industrials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDT icon
26
Medtronic
MDT
$110B
$29.3M 1.15%
326,172
-108,968
-25% -$11M
BIIB icon
27
Biogen
BIIB
$30.7B
$27.7M 1.09%
135,639
– –
JAZZ icon
28
Jazz Pharmaceuticals
JAZZ
$16.2B
$26.2M 1.03%
167,899
+27,426
+20% +$4.22M
ZTS icon
29
Zoetis
ZTS
$31.9B
$25.2M 0.99%
146,714
+5,547
+4% +$959K
SYNH
30
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$21.7M 0.85%
302,945
-78,625
-21% -$5.75M
ISRG icon
31
Intuitive Surgical
ISRG
$126B
$21.3M 0.84%
106,176
+48,570
+84% +$11.4M
HCA icon
32
HCA Healthcare
HCA
$85.7B
$20.9M 0.82%
124,303
– –
ALNY icon
33
Alnylam Pharmaceuticals
ALNY
$27.4B
$18.7M 0.74%
128,414
-30,192
-19% -$4.28M
IDXX icon
34
Idexx Laboratories
IDXX
$44.1B
$18.6M 0.73%
52,910
-8,307
-14% -$3.39M
IQV icon
35
IQVIA
IQV
$39.1B
$18.3M 0.72%
84,303
-13,851
-14% -$3.01M
BDX icon
36
Becton Dickinson
BDX
$45.6B
$18.2M 0.72%
73,930
-1,848
-2% -$469K
ICLR icon
37
Icon
ICLR
$12.8B
$17.6M 0.69%
81,375
-6,862
-8% -$1.54M
UTHR icon
38
United Therapeutics
UTHR
$26.2B
$17M 0.67%
72,206
– –
WELL icon
39
Welltower
WELL
$170B
$16.7M 0.66%
203,083
– –
NBIX icon
40
Neurocrine Biosciences
NBIX
$18.7B
$16.4M 0.64%
168,108
+43,499
+35% +$4.01M
EW icon
41
Edwards Lifesciences
EW
$50B
$16.3M 0.64%
171,388
-5,800
-3% -$600K
SRPT icon
42
Sarepta Therapeutics
SRPT
$1.64B
$15.9M 0.63%
212,165
-15,532
-7% -$1.14M
XBI icon
43
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$15.5M 0.61%
209,154
+113,505
+119% +$8.52M
ZBH icon
44
Zimmer Biomet
ZBH
$18.4B
$14.9M 0.59%
142,044
– –
RMD icon
45
ResMed
RMD
$30.3B
$14.9M 0.58%
70,999
– –
RLYB icon
46
Rallybio
RLYB
$85.3M
$14.6M 0.57%
241,390
-32,986
-12% -$2.48M
ARGX icon
47
argenx
ARGX
$54.6B
$14.6M 0.57%
38,456
– –
NVO
48
Novo Nordisk
NVO
$228B
$14.5M 0.57%
261,046
-46,000
-15% -$2.55M
XLV icon
49
State Street Health Care Select Sector SPDR ETF
XLV
$42.2B
$14.5M 0.57%
113,230
– –
GH icon
50
Guardant Health
GH
$20.2B
$14.2M 0.56%
351,484
– –
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Tekla Capital Management held 180 positions worth $2.54B, down 11% from $2.85B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Trading was light in Q2 2022: portfolio turnover was 4.4%. Tekla Capital Management opened 5 new positions and exited 3, leaving the 180-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q2 2022 buy was Lantheus: 127,092 shares worth $8.39M.
  • Tekla Capital Management added most to Vertex Pharmaceuticals in Q2 2022, an estimated $14M increase.
  • Tekla Capital Management's biggest Q2 2022 reduction was Seagen Inc. Common Stock, cutting an estimated $19.5M.
  • Tekla Capital Management fully exited Revvity in Q2 2022, selling an estimated $5.83M.
  • Tekla Capital Management's ten largest holdings make up 38% of its $2.54B portfolio in Q2 2022.
  • Tekla Capital Management opened 5 new positions and closed 3 in Q2 2022.
  • Tekla Capital Management's portfolio value fell 11% quarter-over-quarter to $2.54B.

Based on Tekla Capital Management's 13F filing for Q2 2022, filed 29 Jul 2022.